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Human cytochrome P450 (CYP) 2A6 metabolizes nicotine to cotinine and is a possible
modulator of nicotine addiction. Quantitative and qualitative differences in nicotine addiction
have been observed between ethnic groups. However, there is little data on the ethnic
influences of the CYP2A6-nicotine metabolism relationship particularly as regards African-
Americans. We determined the nicotine metabolism and CYP2A6genotype in 176 European-
Americans and 160 African-Americans, comparing them with our previous data from 209
Koreans and 92 Japanese. Large interindividual differences were observed in the
cotinine/nicotine ratios in plasma calculated as an index of nicotine metabolism in European-
Americans (0.6 – 36.5) and in African-Americans (0.9 – 30.4). No ethnic difference was
observed between European-Americans (7.2 ± 5.0), African-Americans (7.1 ± 4.7), and
Koreans (8.7 ± 11.9), whereas Japanese showed a significantly (P < 0.005) lower metabolic
ratio (3.8 ± 3.1) than the other populations. Females showed significantly (P < 0.05) higher
metabolic ratios than males in African-Americans (8.0 ± 5.3 vs 6.0 ± 3.7). Obvious ethnic
differences in the CYP2A6 alleles were observed between these four populations. The
combined frequencies of the alleles lacking or showing reduced enzymatic activity
(CYP2A6*2, CYP2A6*4, CYP2A6*5, CYP2A6*7, CYP2A6*9, CYP2A6*10, CYP2A6*11,
CYP2A6*17, CYP2A6*19, and CYP2A6*20) were 9.1, 21.9, 42.9, 50.5% in European-
Americans, African-Americans, Koreans, and Japanese, respectively. These CYP2A6 alleles
were associated with reduced nicotine metabolism. Among the homozygotes of CYP2A6*1,
interindividual and ethnic differences in the metabolic ratio were still observed. Thus, some
factors other than genetic ones might also contribute to the interindividual and ethnic
differences. This comprehensive study of four populations extends our understanding of
nicotine metabolism and the impact of genetic polymorphisms of the CYP2A6 gene.
3INTRODUCTION
Cytochrome P450 (CYP)s, a superfamily of heme-containing monooxygenases, are
involved in the metabolism of drugs, environmental pollutants, dietary chemicals and
endogenous compounds.1 CYP2A6 is responsible for a major metabolic pathway of nicotine.2
Since metabolism is the primary route for the elimination of nicotine, variability in the
metabolism is a determinant of the clearance of nicotine. CYP2A6 is also a possible
modulator of nicotine addiction. 3 We previously evaluated the interindividual differences in
nicotine metabolism in Japanese and Korean non-smokers.4,5 We found that the
cotinine/nicotine ratios calculated as a metabolic index in Korean subjects were significantly
higher than those in Japanese subjects. Many research groups reported that the plasma
cotinine levels in black smokers were higher than those in white smokers.6-11 The plasma
cotinine level greatly depends on the depth of inhalation, the volume of each puff, the force of
drawing.12 Thus, even if the consumption of cigarettes might be taken into consideration, the
absolute values of cotinine concentration could not be used as an index of nicotine
metabolism. In the present study, a phenotyping method using nicotine gum established in our
previous study was applied for non-smokers, in order to determine the interindividual and
interethnic differences in nicotine metabolism between European-Americans and African-
Americans.
The large interindividual differences in nicotine metabolism are associated with genetic
polymorphisms of the CYP2A6 gene.4,5,13,14 Among a variety of alleles, the CYP2A6*2,15,16
CYP2A6*4, 17-19 CYP2A6*5 20 alleles are known to cause a lack of enzymatic activity. The
alleles of CYP2A6*6,21 CYP2A6*7,22 CYP2A6*9,14 CYP2A6*10,13 CYP2A6*11,23 CYP2A6*12
24 are known to decrease enzymatic activity. Recently, we found CYP2A6*17,25 CYP2A6*18,26
CYP2A6*19,26 and CYP2A6*20 27 alleles. The CYP2A6*17 and CYP2A6*19 alleles decrease
the enzymatic activity and the CYP2A6*20 allele produces a truncated protein with no activity.
Furthermore, several single nucleotide polymorphisms (SNPs) were reported in the 5’-
flanking region of the CYP2A6 gene.28,29 In the present study, we exhaustively analyzed that
4the interindividual, ethnic, and sex differences in nicotine metabolism and the genetic
polymorphisms of the CYP2A6 gene in European-Americans, African-Americans, Koreans,
and Japanese. Since we had previously determined through CYP2A6*11 for Koreans and
Japanese, 4,5,13,14 we expanded the genotyping analyses through CYP2A6*22and CYP2A6*1
sub-alleles in the present study. This is the first study to determine the CYP2A6 phenotype
and genotype in African-Americans. It has been reported that there were systematic
differences in the absolute values of nicotine and cotinine concentrations between
laboratories.30 Therefore, the strength of the present study is that we used a unified
phenotyping protocol, analytical method and apparatus to measure the plasma concentrations
of nicotine and cotinine, and the same genotyping method for all populations.
METHODS
Chemicals and Regents.
  Taq polymerase was obtained from Greiner Japan (Tokyo, Japan). Ex Taq polymerase and
Takara LA Taq DNA polymerase were purchased from Takara (Shiga, Japan). Restriction
enzymes were purchased from Takara, Toyobo (Osaka, Japan), New England Biolabs
(Beverly, MA) and Fermentas (Hanover, MD). Primers were commercially synthesized at
Hokkaido System Sciences (Sapporo, Japan). Nicorette® (nicotin  gum containing 2 mg of
nicotine) was obtained from Pfizer Japan (Tokyo, Japan). All other chemicals and solvents
were of the highest grade commercially available.
Phenotyping of In Vivo Nicotine Metabolism.
   This study was approved by the Human Studies Committee of Washington University
School of Medicine (St. Louis, MO) and the Ethics Committees of Kanazawa University
(Kanazawa, Japan) and Soonchunhyang University Hospital (Chonan, Korea). Written
informed consent was obtained from all subjects. Healthy non-smokers were recruited. No
subjects were taking any medications. Exclusion criteria included pregnancy, drug or alcohol
5abuse, and abnormal liver, renal, or cardiac function. In our previous studies, 4,5 209 Korean
subjects (18 – 47 years old, 58.3 ± 9.7 kg, 78 males and 131 females) and 92 Japanese
subjects (19 – 39 years old, 56.3 ± 10.7 kg, 37 males and 55 females) were already
phenotyped for in vivo nicotine metabolism. In the present study, 187 European-American
subjects (19 – 47 years old, 78.7 ± 20.7 kg, 87 males and 100 females) and 176 African-
American subjects (18 – 45 years old, 92.5 ± 28.1 kg, 87 males and 89 females) were
recruited. The subjects chewed one piece of nicotine gum (Nicorette®) for 30 min, chewing
for 10 sec per 30 sec. Blood samples were collected from a cubital vein just before and 2 hr
after the start of chewing. Separated plasma and buffy coat samples were stored at –20°C until
analyzed. It has been confirmed that nicotine and cotinine in plasma are stable for >1 year
under the condition. All samples with dry ice were shipped to Kanazawa University
(Kanazawa, Japan) and the concentrations of nicotine and cotinine in the plasma samples
were determined by HPLC as described previously.31 The cotinine/nicotine ratio of the plasma
concentration was calculated as an index of the nicotine metabolism. We previously
confirmed that the intraindividual changes in the cotinine/nicotine ratio were at most 6%. 32
Probit transformations of the data were conducted as described previously.4 Plasma
concentrations of nicotine and cotinine before chewing one piece of nicotine gum were
measured to confirm non-smoking. Since 11 out of 187 European-Americans and 16 out of
176 African-Americans were judged as smokers based on the baseline presence of nicotine
and cotinine, the phenotyping was not performed in these subjects.
Genotyping of CYP2A6 Alleles.
Genomic DNA from all subjects was extracted from peripheral lymphocytes using a
Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN). The primers used in the
present study are shown in Table I. The genotyping of CYP2A6*1X2 (duplication),13
CYP2A6*2 (L160H),12 CYP2A6*3 (CYP2A6/CYP2A7 hybrid),12 CYP2A6*4A (entire gene
deletion),33 CYP2A6*4D (entire gene deletion),33 CYP2A6*5 (G479V),4 CYP2A6*6
(R128Q),13 CYP2A6*7 (I471T),13 CYP2A6*8 (R485L),13 CYP2A6*10 (I471T and R485L),13
6CYP2A6*11 (S224P),13 CYP2A6*12 (10 amino acid substitutions),34 CYP2A6*13 (g.-48T>G
and G5R),26 CYP2A6*14 (S29N),26 CYP2A6*15 (g.-48T>G and K194E),26 CYP2A6*16
(R203S),26 CYP2A6*17 (V365M),25 CYP2A6*18 (Y392F),26 CYP2A6*19 (Y392F and
I471T),26 and CYP2A6*20 (frameshift)27 were performed as described previously.
An allele specific (AS)-PCR method for the CYP2A6*9 allele (g.-48T>G and g.-
1013A>G) targeting the SNP of g.-48T>G was modified in the present study. The sense
primers were 2A6*9-wt-S or 2A6*9-mut-S and the antisense primer was 2A6int1AS (Table I).
The PCR product (385 bp) was analyzed by electrophoresis with 2% agarose gel. The
genotyping method for the CYP2A6*21 allele (K476R) with AS-PCR was established in the
present study. The sense primers were 2A6*21-wt or 2A6*21-mut and the antisense primer
was 2A6R2 (Table I). The PCR product (421 bp) was analyzed by electrophoresis with 2%
agarose gel. A PCR-RFLP method was developed for the genotyping of the CYP2A6*22 allele
(D158E and L160I) targeting the SNP of g.1794C>G. Primers were 2A6int2F and 2A6ex3R1
(Table I). The PCR product was digested with EcoN I. The CYP2A6*1 allele yields a 270-bp
fragment and the CYP2A6*22 allele yields 233- and 37-bp fragments.
The SNPs of g.-1013A>G and g.-745A>G were genotyped by PCR-RFLP and AS-PCR
in combination. In the first PCR (PCR I), the sense primer was 2A6-1188F and the antisense
primers were 2A6-745wt-AS or 2A6-745mut-AS (Table I). The PCR product was digested
with Bgl II. The digestion patterns were determined by electrophoresis in a 2% agarose gel
(Fig 1). The alleles possessing g.-1013A and g.-745A were assigned to type I. In this type, the
alleles were classified as CYP2A6*1A or CYP2A6*1B1, based on the sequences in 3’-UTR
that are derived from the CYP2A6 or CYP2A7 sequences, respectively. The genotyping of 3’-
UTR was performed by the method that we previously reported.33 Th  alleles possessing g.-
1013G and g.-745A were assigned to type II. In this type, the alleles were classified as
CYP2A6*1D or CYP2A6*1B2, based on the sequences in 3’-UTR that are derived from the
CYP2A6 or CYP2A7 sequences, respectively. The alleles possessing g.-1013A and g.-745G
were assigned to type III. The allele in which the 3’-UTR has the CYP2A6 sequence is the
CYP2A6*1H allele. In this study, we found a novel allele possessing g.-1013A, g.-745G and
7gene conversion with CYP2A7 in 3’-UTR. This allele was termed CYP2A6*1B13 by the
Human CYP Allele Nomenclature Committee. The allele possessing g.-1013G and g.-745G
was assigned to type IV. In this type, only the CYP2A6*1J allele was found. Thus, the
CYP2A6*1A, CYP2A6*1B1, CYP2A6*1B2, CYP2A6*1B13, CYP2A6*1D, CYP2A6*1H, and
CYP2A6*1J alleles were genotyped by the SNPs of g.-1013A>G and g.-745A>G as well as
the sequences in 3’-UTR.  
If the subjects are typed as I/II, the genotypes of CYP2A6*1A/CYP2A6*1B2 or
CYP2A6*1B1/CYP2A6*1D are possible. In addition, for the type I/III, the genotypes of
CYP2A6*1A/CYP2A6*1B13 or CYP2A6*1B1/CYP2A6*1H are possible. For the type II/III,
the genotypes of CYP2A6*1B2/CYP2A6*1H or CYP2A6*1D/CYP2A6*1B13 are possible. To
determine the genotype, a second PCR (PCR II) was performed. Sense primers were 2A6-
1013A-S or 2A6-1013G-S and the antisense primer was 2A7UTR-RV (Table I). Using the
LA-PCR product (7753 bp) as the template, the PCR I was performed as described above.
Data Analysis.
Fisher's exact test was used to compare the observed and calculated genotype
frequencies. The expected genotype frequencies were calculated using the Hardy-Weinberg
equation. The Kruskal-Wallis test or Mann-Whitney U-test was used to investigate the ethnic
and sex differences in metabolic ratios. P < 0.05 was considered statistically significant.
RESULTS
Interindividual and Interethnic Differences in Nicotine Metabolism.
     Phenotyping data from 176 European-Americans (82 males and 94 females) and 160
African-Americans (75 males and 85 females) were analyzed. In European-Americans (n =
176), the plasma concentrations of nicotine and cotinine were 2.3 ± 1.2 ng/ml and 13.3 ± 6.0
ng/ml, respectively. The cotinine/nicotine ratios of the plasma concentration calculated as an
index of nicotine metabolism ranged from 0.6 – 36.5 (7.2 ± 5.0) (Table II). In African-
8Americans (n = 160), the plasma concentrations of nicotine and cotinine were 2.2 ± 1.1 ng/ml
and 13.2 ± 6.6 ng/ml, respectively. The cotinine/nicotine ratios ranged from 0.9 – 30.4 (7.1 ±
4.7). Thus, large interindividual differences in nicotine metabolism were observed. Among the
present four populations, the Japanese revealed a significantly (P < 0.005) lower metabolic
ratio than the other populations. The ethnic differences were also obvious in the probit plots of
the cotinine/nicotine ratios (Fig 2), since the plots of the Japanese were shifted to the left from
the plots of the other populations. These results indicated that Japanese have significantly
lower capability for nicotine metabolism than other populations.
Sex Differences in Nicotine Metabolism.
     The probit plots of cotinine/nicotine ratios were separately made for males and females
(Fig 3). In European-Americans, the plots of the cotinine/nicotine ratios in females shifted to
the right from those in males up to the ratio of 10. It was reversed over the ratio of 10. Overall,
there was no statistical difference between females and males (Table II). In African-
Americans, Koreans, and Japanese, the probit plots of the ratio in females shifted to the right
from those in males on the whole. Thus, the ratios in females were higher than in males (Table
II), although a statistical difference was observed only in African-Americans (P < 0.05).
These results suggested that the capability for nicotine metabolism might be higher in females
than in males.
Allele Frequencies of CYP2A6 Alleles.
     The genotyping of the CYP2A6 gene was performed for 187 European-Americans, 176
African-Americans, 209 Koreans, and 92 Japanese (Table III). The genotype frequencies were
in accordance with the Hardy-Weinberg equation. No sex difference was observed in the
allele frequencies in any population (data not shown). The only allele found in all populations
was CYP2A6*9, although the frequencies could be divided roughly into two groups:
Americans and Asians. In European-Americans, the alleles of CYP2A6*2, CYP2A6*14,
CYP2A6*16, and CYP2A6*21 were found. These alleles were also found in African-
9Americans, but not in Koreans and Japanese. In addition, in African-Americans, CYP2A6*4A,
CYP2A6*4D, CYP2A6*17, and CYP2A6*20 were found, whereas CYP2A6*18 was found in
European-Americans.
     In Koreans and Japanese, the alleles of CYP2A6*4A, CYP2A6*7, CYP2A6*8,
CYP2A6*10, CYP2A6*11, CYP2A6*13, CYP2A6*15 were found in common. It should be
emphasized that the allele frequency of CYP2A6*4A was prominently higher in Japanese than
in the other populations. In Koreans, the alleles of CYP2A6*1X2, CYP2A6*18, and
CYP2A6*19 were also found.
SNPs in the 5’-Flanking Region and Gene Conversion in 3’-Untranslated Region.
     The homozygotes of CYP2A6*1 (126 European-Americans, 91 African-Americans, 64
Koreans, and 22 Japanese) were next subjected to the genotyping of the CYP2A6*1A,
CYP2A6*1B1, CYP2A6*1B2, CYP2A6*1B13, CYP2A6*1D, CYP2A6*1H, and CYP2A6*1J
alleles. In this analysis, we found an African-American subject who possessed three alleles of
CYP2A6*1A, CYP2A6*1D, and CYP2A6*1H. If the subject had been genotyped for the
duplication allele of CYP2A6*1X2, it would mean that he has three CYP2A6alleles. However,
he was not genotyped for the CYP2A6*1X2 allele. We confirmed that the relative gene copy
number ratio of CYP2A6/CYP2A7 in exon 3 or exon 5 in this subject was 1.5 (data not
shown).33 These results suggested that he would have a novel duplication allele other than the
CYP2A6*1X2 allele. Therefore, the number of alleles in 91 African-Americans was suspected
to be 183 as shown in Table IV. The CYP2A6 gene structure in this subject is now being
analyzed in detail in our laboratory.
     The frequency of the CYP2A6*1A allele was higher than that of the CYP2A6*1B1 allele
in all populations. In European-Americans and African-Americans, the frequencies of
CYP2A6*1D were higher than those of CYP2A6*1B2, but the frequencies of CYP2A6*1B2
were higher than those of CYP2A6*1D in Koreans and Japanese. The frequencies of
CYP2A6*1H were higher than those of CYP2A6*1B13 in European-Americans and African-
Americans, but the frequencies of CYP2A6*1B13 were higher than those of CYP2A6*1H in
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Koreans and Japanese. The CYP2A6*1J allele was not found in any population in this study.
Effects of Genetic Polymorphisms of CYP2A6 on Nicotine Metabolism.
    The cotinine/nicotine ratios in homozygotes of CYP2A6*1 were compared among
different sub-genotypes (Table V). We could not find any association between the CYP2A6*1
sub-genotypes and the phenotype. Therefore, the CYP2A6*1 sub-genotypes were regarded as
CYP2A6*1 in further analyses. In addition, the CYP2A6*4A and CYP2A6*4D alleles were
regarded as CYP2A6*4, since both alleles delete the entire CYP2A6 gene.
In European-Americans, the mean cotinine/nicotine ratio in homozygotes of CYP2A6*1
was 7.7 ± 5.5 (Table VI). The heterozygotes of CYP2A6*1appeared to show ratios similar to
those of homozygotes of CYP2A6*1. Although statistical analysis could not be performed
because of the limited number of samples, 2 subjects with CYP2A6*2/CYP2A6*9 revealed
lower nicotine metabolic ratios. In contrast, 2 subjects with CYP2A6*9/CYP2A6*18 revealed
moderate ratios, indicating that the effects of mutation of CYP2A6*18 would be weak on
nicotine metabolism. A homozygote of CYP2A6*14 revealed a relatively low ratio.
In African-Americans, the mean cotinine/nicotine ratio in homozygotes of CYP2A6*1
was 8.1 ± 5.1. The subjects with CYP2A6*1/CYP2A6*14 revealed significantly higher
nicotine metabolic ratios compared with homozygotes of CYP2A6*1. Since a European-
American CYP2A6*14 homozygote revealed a relatively low ratio, we could not find the
effects of the CYP2A6*14 allele on in vivo nicotine metabolism. As we previously reported,25
the subjects with CYP2A6*1/CYP2A6*17 or CYP2A6*17/CYP2A6*17 revealed significantly
(P < 0.05) lower metabolic ratios compared with homozygotes of CYP2A6*1. Furthermore,
the subjects with CYP2A6*4/CYP2A6*9, CYP2A6*9/CYP2A6*9, CYP2A6*9/CYP2A6*17 ,
CYP2A6*14/CYP2A6*17 , CYP2A6*17/CYP2A6*20 , and CYP2A6*20/CYP2A6*21 also
revealed relatively low metabolic ratios, although we could not perform statistical analysis
because of the limited number of subjects. In addition, the subjects with
CYP2A6*1/CYP2A6*2, CYP2A6*1/CYP2A6*4, or CYP2A6*1/CYP2A6*20 also revealed
relatively low metabolic ratios. Thus, the subjects with CYP2A6*2, CYP2A6*4, CYP2A6*17,
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CYP2A6*20 alleles revealed low nicotine metabolism activity. Subjects with
CYP2A6*16/CYP2A6*16 or CYP2A6*16/CYP2A6*17 revealed a similar nicotine metabolic
ratio compared to the homozygotes of CYP2A6*1, indicating that the CYP2A6*16 allele
might not affect the enzymatic activity.
In Koreans, the mean cotinine/nicotine ratio in homozygotes of CYP2A6*1 was 13.7 ±
18.7. The subjects with CYP2A6*1/CYP2A6*7 or CYP2A6*1/CYP2A6*15 revealed a
significantly (P < 0.05) lower nicotine metabolic ratio compared with homozygotes of
CYP2A6*1. As we previously reported, the subjects possessing two alleles of CYP2A6*4,
CYP2A6*7, CYP2A6*9, CYP2A6*10, and CYP2A6*19 in combination revealed low nicotine
metabolic ratios. Especially, the metabolic ratios of the homozygotes of CYP2A6*4 were zero.
Our result that a subject with CYP2A6*7/CYP2A6*11 revealed a low nicotine metabolic ratio
(2.9) was consistent with a previous in vitro study showing that CYP2A6.11 had decreased
enzymatic activity.23 A subject with CYP2A6*11/CYP2A6*13 revealed a relatively low
nicotine metabolic ratio. The subjects with CYP2A6*1/CYP2A6*15 revealed significantly (P
< 0.05) lower nicotine metabolic ratios than the subjects with CYP2A6*1/CYP2A6*9.
In Japanese, the mean cotinine/nicotine ratio in homozygotes of CYP2A6*1 was 5.7 ±
4.0. Similar to Koreans, the subjects possessing two alleles of CYP2A6*4, CYP2A6*7,
CYP2A6*9, and CYP2A6*10 in combination revealed low nicotine metabolic ratios.
Especially, the metabolic ratios of the homozygotes of CYP2A6*4 were zero. A subject with
CYP2A6*7/CYP2A6*13 revealed a relatively low nicotine metabolic ratio, suggesting that the
CYP2A6*13 allele might cause the decreased activity. A subject with CYP2A6*4/CYP2A6*15
revealed a similar nicotine metabolic ratio to that in the subjects with CYP2A6*4/CYP2A6*9,
indicating that the CYP2A6*15 allele also might cause the decreased activity. The
CYP2A6*13 and CYP2A6*15 alleles have the SNP in the TATA box (g.-48T>G) found in the
CYP2A6*9 allele as well as the SNPs leading to amino acid changes of G5R and K194E,
respectively.35 Although the effects of the amino acid changes on the enzymatic activity
remain to be investigated in vitro, we clarified that CYP2A6*13 and CYP2A6*15 decreased
the enzymatic activity n vivo.
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     If a probit plot produces curved or broken lines, it indicates that each data point is not
normally distributed. Although the plots of Koreans and Japanese had antimode of
approximately 0.6, those of European-Americans and African-Americans did not show a clear
antimode. This would be due to the fact that there were no subjects possessing two alleles
with dramatically decreased or lacking enzymatic activity among European-Americans and
African-Americans.
Interindividual, Ethnic, and Sex Differences in Nicotine Metabolism in Homozygotes of
CYP2A6*1.
     Among the homozygotes of CYP2A6*1, the interindividual differences in the metabolic
ratio were still large in European-Americans (0.6 – 36.5, 7.7 ± 5.5), African-Americans (0.9 –
30.4, 8.1 ± 5.1), Koreans (1.8 – 143.9, 13.7 ± 18.7), and Japanese (0.9 – 14.7, 5.7 ± 4.0) (Fig
4, Table VI). The mean metabolic ratio in Japanese was significantly (P < 0.05) ower than
those in African-Americans and Koreans. On the other hand, the mean metabolic ratio in
Koreans was significantly (P < 0.005) higher than in the other populations (Table VI).
     In European-Americans, the mean metabolic ratios in females (n = 72) tended to be
lower than that in males (n = 54) (7.1 ± 3.4 vs 8.4 ± 7.4). In contrast, in African-Americans
(42 females and 48 males), Koreans (45 females and 19 males), and Japanese (10 females and
12 males), the mean metabolic ratios in females tended to be higher than that in males (9.3 ±
6.0 vs 7.1 ± 3.9, 14.1 ± 20.9 vs 13.0 ± 12.7, and 7.5 ± 4.7 vs 4.2 ± 2.6, respectively). However,
no statistical difference was observed.
DISCUSSION
Nicotine is responsible for the addiction to smoking which is associated with a higher
incidence of various types of cancers, respiratory and cardiovascular disease, gastrointestinal
disorders as well as many other medical complications.36 Nicotine has roles in replacement
therapy for smoking cessation and has been studied as an experimental therapy for several
diseases such as Parkinson's disease, Alzheimer's disease, and ulcerative colitis.37-39 Therefore,
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the variability of nicotine metabolism would have an impact on various clinical outcomes.
Furthermore, several research groups have reported that smoking behavior and lung cancer
risk are related to genetic polymorphisms of the CYP2A6 g ne.3,40 In the present study, we
determined the interindividual, ethnic, and sex differences in nicotine metabolism and genetic
polymorphisms of the CYP2A6 gene in European-Americans, African-Americans, Koreans,
and Japanese. We found that there was no significant difference in the nicotine metabolic ratio
between European-Americans and African-Americans. Therefore, the differences in plasma
cotinine levels between white and black people that were reported previously would not be
due to differences in the nicotine metabolism activity. As previously reported, it may be that
blacks take in significantly more nicotine per cigarette compared with whites,10 or blacks have
significantly lower clearance of cotinine than whites.41 Since cotinine is metabolized to trans-
3’-hydroxycotinine by CYP2A642 and N-glucuronide by UGT1A4,43 Benowitz et al.41
considered that the observed slow metabolism of cotinine in blacks may be due to reduced
CYP2A6 activity and glucuronidation activity. However, in the present study, we were able to
exclude ethnic differences in the CYP2A6 activity between European-Americans and African-
Americans. CYP2A6 catalyzes the metabolic activation of tobacco-specific nitrosamines such
as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).44 The incidence of lung cancer
has been reported to be greater in blacks compared with whites.45 Since we found no ethnic
difference in CYP2A6 activity between blacks and whites, the difference in the incidence of
lung cancer might be because blacks inhale more deeply, which could be a reason for smoking
mentholated cigarettes,46 r ulting in greater carcinogen exposure.
We found that the nicotine metabolism potency in Japanese was significantly lower
than that in other populations. This result was consistent with a previous in vitrostudy to
showing that the coumarin 7-hydroxylation activity in liver microsomes from Japanese was
lower than that in liver microsomes from Caucasians.47 One of the reasons for the low
CYP2A6 activity in Japanese would be a prominently high frequency of CYP2A6*4 alleles
(19.0%). There were ethnic differences in the allele frequencies of the CYP2A6 gene. The
combined frequencies of the alleles lacking or showing reduced enzymatic activity
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(CYP2A6*2, CYP2A6*4, CYP2A6*5, CYP2A6*7, CYP2A6*9, CYP2A6*10, CYP2A6*11,
CYP2A6*17, CYP2A6*19, and CYP2A6*20) were 9.1, 21.9, 42.9, 50.5% in European-
Americans, African-Americans, Koreans, and Japanese, respectively. It should be noted that
the interindividual differences in the metabolic ratio were still large among the homozygotes
of CYP2A6*1. Furthermore, among the homozygotes of CYP2A6*1, Japanese revealed
significantly lower nicotine metabolism than African-Americans and Koreans, whereas
Koreans revealed significantly higher nicotine metabolism than the other populations.
Therefore, some factors other than genetic ones, such as diet and/or environmental factors as
well as unknown or uncharacterized alleles might contribute to the interindividual and ethnic
differences. In addition, we may have to consider differences in the post-transcriptional or
post-translational regulation of CYP2A6.
Concerning the SNPs in the 5’-flanking region of the CYP2A6 gene, we analyzed three
SNPs of g.-1013A>G, g.-745A>G, and g.-48T>G. It has been reported that these SNPs
decrease the transcriptional activity in luciferase assays.28,29,48The CYP2A6 mRNA level,
protein level, and enzymatic activity have been reported to be decreased by the SNP of g.-
48T>G in human livers,14,49 but not by g.-1013A>G.50 For the SNP of g.-745A>G, increased
mRNA level in human livers has been reported.50 In th  present study, we found no significant
effects of the SNPs of g.-1013A>G and g.-745A>G on in vivo nicotine metabolism (Table V).
Sex differences (female > male) in nicotine metabolism were observed in the present
study. Previously, Zeman et al.51 have reported that the ratio of nicotine/(cotinine + 3’-
hydroxycotinine) in 24-hr urine was significantly lower in females compared with males.
Benowitz et al.52 has clearly shown that nicotine and cotinine clearances are higher in females
compared with males after intravenous infusion of both nicotine and cotinine. In addition, it
has been reported that the urinary excretion of 7-hydroxycoumarin was higher in females
compared with males.53,54 An in vitro study revealed that the coumarin 7-hydroxylation
activity in liver microsomes obtained from females was higher than in those obtained from
males.55 Our results and these previous papers suggested that CYP2A6 activity in females is
higher than in males. It has been reported that nicotine and cotinine clearance is higher in
15
pregnancy compared with postpartum56 and is accelerated by oral contraceptive use in
females.52 Females have higher concentrations of estrogens and progesterone than males; the
concentrations of these sex hormones are increased with the use of oral contraceptives or
during pregnancy. Thus, these hormones might possibly induce CYP2A6. Further study is
needed to clarify the mechanism of the sex differences in CYP2A6 activity.
     In conclusion, we comprehensively determined the interindividual, ethnic, and sex
differences in nicotine metabolism and genetic polymorphisms of the CYP2A6 gene in
European-Americans, African-Americans, Koreans, and Japanese. The findings in this study
extend our understanding of nicotine metabolism and the impact of genetic polymorphisms of
the CYP2A6 gene.
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Figure legend
Fig 1. Genotyping of CYP2A6*1 sub-alleles by PCR-RFLP and AS-PCR in combination. A,
Schematic structures of CYP2A6 gene. Open and dotted boxes represent exons of CYP2A6
and CYP2A7, respectively. Lines represent 5’-flanking regions or introns. PCR amplification
was performed with the primer pairs indicated by horizontal arrows. The primer 2A6-745wt-
AS specifically anneals to the CYP2A6*1A, CYP2A6*1B1, CYP2A6*1B2, CYP2A6*1D alleles,
whereas the primer 2A6-745mut-AS specifically anneals to the CYP2A6*1H, CYP2A6*1J,
and CYP2A6*1B13 alleles. The amplified product was digested with Bgl II. The restriction
sites of Bgl II are indicated by vertical arrows. B, Schematic PCR-RFLP patterns for different
CYP2A6 genotypes. After digestion with Bgl II, CYP2A6*1A and CYP2A6*1B1 alleles yield
286-bp and 195-bp fragments in the primer pair of 2A6-1188F and 2A6-745wt-AS;
CYP2A6*1D and CYP2A6*1B2 alleles yield 481-bp fragment in the primer pair of 2A6-1188F
and 2A6-745wt-AS; CYP2A6*1H and CYP2A6*1B13 alleles yield 286-bp and 195-bp
fragments in the primer pair of 2A6-1188F and 2A6-745mut-AS; CYP2A6*1J allele yields
481-bp fragment in the primer pair of 2A6-1188F and 2A6-745mut-AS.
Fig 2. Probit analysis for cotinine/nicotine ratios of the plasma concentration 2 hr after
chewing one piece of nicotine gum in 176 European-Americans, 160 African-Americans, 209
Koreans and 92 Japanese. The abscissa denotes the cotinine/nicotine ratio of the plasma
concentration in different individuals. The ordinate represents the percent area under the
normal probability curve for each data point. The plots for Koreans and Japanese were quoted
from our previous study.4,5
Fig 3. Probit analysis for cotinine/nicotine ratios of the plasma concentration 2 hr after
chewing one piece of nicotine gum. A, 94 Female and 82 male European-Americans, B, 85
female and 75 male African-Americans, C, 131 female and 78 male Koreans and D, 55
female and 37 male Japanese. The abscissa denotes the cotinine/nicotine ratio of the plasma
23
concentration in different individuals. The ordinate represents the percent area under the
normal probability curve for each data point.
Fig 4. The cotinine/nicotine ratios in subjects with different CYP2A6 genotypes. A, 176
European-Americans, B, 160 African-Americans, C, 209 Koreans, and D, 92 Japanese.
Circles show each subject and bars show the mean of each group. *P < 0.05, compared with
the homozygotes of CYP2A6*1.
 Table I. Primers used in the present study
     Primer             Sequence    Location
2A6-1188F      5’-CTGACAAAGCAGGAATCATT-3’5’-flanking region
2A6-1013A-S 5’-GTCTGTTTTCTGTCCTCTGTA-3’5’-flanking region
2A6-1013G-S 5’-GTCTGTTTTCTGTCCTCTGTG-3’5’-flanking region
2A6-745wt-AS 5’-TCCACTGCCCATCTCTGAT-3’ 5’-flanking region
2A6-745mut-AS 5’-TCCACTGCCCATCTCTGAC-3’ 5’-flanking region
2A6*9-wt-S 5’-TCCCTCTTTTTCAGGCAGGCAGTAT-3’ 5’-flanking region
2A6*9-mut-S 5’-TCCCTCTTTTTCAGGCAGGCAGTAG-3’ 5’-flanking region
2A6int1ASa 5’-TCCTGTCTTTCTGATGCTGA-3’ intron 1
2A6int2F 5’-TGTCTCCATTCCCGCGTTC-3’ intron 2
2A6ex3R1b 5’-GTCCCCTGCTCACCGCCA-3’ exon 3
2A6*21-wt 5’-CATTGACGTGTCCCCCAA-3’ exon 9
2A6*21-mut 5’-CATTGACGTGTCCCCCAG-3’ exon 9
2A7UTR-RV 5’-ATTCTTATACCCGCCTCTTCCGCGAA-3’ 3’-untranslated region
2A6R2c 5’-AAAATGGGCATGAACGCCC-3’ 3’-flanking region
aData from Fukami et al.25
bData from Oscarson et al.24
cData from Oscarson et al.17
Table II. The cotinine/nicotine ratios in four populations
Population Overall Female Male
European-Americans 7.2 ±   5.0    (n = 176) 7.1 ±   3.6    (n =   94) 7.2 ± 6.3    (n = 82)
African-Americans    7.1 ±   4.7    (n = 160) 8.0 ±   5.3†    (n =   85) 6.0 ± 3.7     (n = 75)
Koreans                8.7 ± 11.9    (n = 209) 9.4 ± 13.6    (n = 131) 7.7 ± 8.2    (n = 78)
Japanese                 3.8 ±   3.1*  (n =   92) 4.1 ±   3.5 * (n =   55) 3.3 ± 2.4 *  (n = 37)
n: number of subjects.
* P < 0.005, Japanese showed significantly lower nicotine metabolic ratio than the other populations.
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Table VI. The cotinine/nicotine ratios in four populations
CYP2A6 genotype European-Americans African-Americans         Koreans        Japanese
(number of subjects)          (n = 176)        (n = 160)                            (n = 209)          (n = 92)
CYP2A6*1/CYP2A6*1 7.7 ± 5.5 (n = 126)   8.1 ± 5.1     (n = 90)13.7 ± 18.7§  (n = 64) 5.7 ± 4.0
†
   (n = 22)
CYP2A6*1/CYP2A6*1X2 12.5                (n =   1)
CYP2A6*1/unknown   4.6              (n =   1)
CYP2A6*1/CYP2A6*2 4.7          (n =     2)   1.3              (n =   1)
CYP2A6*1/CYP2A6*4   3.4              (n =   2)  7.9 ±   4.2     (n = 24)3.9 ± 2.0     (n = 16)
CYP2A6*1/CYP2A6*5 10.3                (n =   2)
CYP2A6*1/CYP2A6*7   7.1 ±   4.2 * (n = 19) 4.9 ± 1.5     (n =   4)
CYP2A6*1/CYP2A6*8 11.6 ±   7.6     (n =   3)5.6              (n =   1)
CYP2A6*1/CYP2A6*9 5.8 ± 3.1 (n = 25)   7.4 ± 4.0     (n = 22)  9.5 ±   8.3     (n = 37)5.0 ± 3.5     (n = 14)
CYP2A6*1/CYP2A6*10 4.4              (n =   2)
CYP2A6*1/CYP2A6*11   5.2               (n =   1)
CYP2A6*1/CYP2A6*13 3.0              (n =   1)
CYP2A6*1/CYP2A6*14 6.4 ± 4.4 (n = 11) 13.7 ± 3.4 * (n =   3)
CYP2A6*1/CYP2A6*15   3.4 ±   2.0 * (n =   4) 2.5              (n =   1)
CYP2A6*1/CYP2A6*16 7.1          (n =   1)   5.2 ± 1.0     (n =   3)
CYP2A6*1/CYP2A6*17   5.2 ± 3.0 * (n = 22)
CYP2A6*1/CYP2A6*18 5.7 ± 3.3 (n =   5)   5.2                (n =   2)
CYP2A6*1/CYP2A6*19   6.8                (n =   2)
CYP2A6*1/CYP2A6*20   3.1              (n =   2)
CYP2A6*1/CYP2A6*21 8.9          (n =   1)   4.0              (n =   1)
CYP2A6*2/CYP2A6*9 1.8          (n =   2)
CYP2A6*4/CYP2A6*4   0.0                (n =   4)0.0              (n =   3)
CYP2A6*4/CYP2A6*7   1.8 ±   1.2 * (n =   4) 0.8 ± 0.6     (n =   5)
CYP2A6*4/CYP2A6*9   0.9              (n =   1)  2.6 ±   0.8 * (n =   8) 1.8 ± 0.9 * (n =   7)
CYP2A6*4/CYP2A6*10   0.1                (n =   1)
CYP2A6*4/CYP2A6*15 2.4              (n =   1)
CYP2A6*7/CYP2A6*7   1.0                (n =   1)1.1              (n =   1)
CYP2A6*7/CYP2A6*9   5.0 ±   3.8 * (n = 10) 1.7 ± 0.7 * (n =   4)
CYP2A6*7/CYP2A6*10   2.2 ±   1.6 * (n =   3) 0.4              (n =   2)
CYP2A6*7/CYP2A6*11   2.9                (n =   1)
CYP2A6*7/CYP2A6*13 0.9              (n =   1)
CYP2A6*7/CYP2A6*15   6.0                (n =   1)
CYP2A6*7/CYP2A6*19   0.8                (n =   1)
CYP2A6*8/CYP2A6*9   2.8                (n =   2)1.2              (n =   1)
CYP2A6*9/CYP2A6*9   3.0              (n =   2)  4.1 ±   2.4 * (n = 12) 2.7 ± 0.4     (n =   4)
CYP2A6*9/CYP2A6*11 4.2              (n =   1)
CYP2A6*9/CYP2A6*17   3.5              (n =   1)
CYP2A6*9/CYP2A6*18 6.4          (n =   2)
CYP2A6*9/CYP2A6*19   2.7                (n =   1)
CYP2A6*11/CYP2A6*13   2.5                (n =   1)
CYP2A6*14/CYP2A6*143.4          (n =   1)
CYP2A6*14/CYP2A6*17   3.9              (n =   1)
CYP2A6*15/CYP2A6*15 4.4              (n =   1)
CYP2A6*16/CYP2A6*16   6.8              (n =   1)
CYP2A6*16/CYP2A6*17   9.2              (n =   1)
CYP2A6*17/CYP2A6*17   2.3 ± 0.5 * (n =   4)
CYP2A6*17/CYP2A6*20   1.9              (n =   1)
CYP2A6*20/CYP2A6*21   3.4              (n =   1)
*P < 0.05, compared with CYP2A6*1/CYP2A6*1 by Mann-Whitney U-test.
† P < 0.05, Japanese showed significantly lower nicotine metabolic ratio than African-Americans and Koreans.












Fig. 1. Nakajima et al.

































































































Fig. 3. Nakajima et al.
Cotinine/nicotine ratio of plasma concentration 






































Fig. 4. Nakajima et al.
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